ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0905

Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry

Eren-Ajani Tshimanga1, Milena Gianfrancesco2, Stefanos Giampanis3, Jing Li2, Emma Kersey4, Jinoos Yazdany5, Beau Norgeot6, Gabriela Schmajuk7 and Zara Izadi4, 1University of California, Berkeley, Berkeley, CA, 2University of California, San Francisco, San Francisco, CA, 3Anthem, San Francisco, 4University of California San Francisco, San Francisco, CA, 5UCSF, San Francisco, CA, 6Anthem, Oakland, CA, 7UCSF / SFVA, San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Disease Activity, Epidemiology, informatics, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Predicting the trajectory of disease in individuals with RA is difficult, with numerous factors influencing whether a patient may experience higher or lower disease activity at their next visit. Machine learning (ML) models that leverage variables available in electronic health records (EHRs) from a large number of patients have been used in many medical contexts to make predictions about the future. We assessed the ability of various ML models to predict disease activity in individuals with RA at future clinical visits using information from the current visit.

Methods: We used data through March 2021 from the ACR’s RISE registry, a large, national EHR-based registry. We included individuals with ≥ 2 RA diagnoses (ICD-9: 714.0) ≥ 30 days apart, and ≥ 2 recorded clinical disease activity index (CDAI) scores ≥ 3 months apart. Disease activity was categorized into four levels (remission, low, moderate, and high activity) based on accepted score ranges. Data features used as predictors included age, sex, race, ethnicity, smoking, obesity, medications, and the previous visit’s CDAI score. Missing data were imputed using last observation carried forward. Variables based on patient ZIP codes from the AHRQ SDOH Database were selected using LASSO and included in the models (total weighted population, per capita income, median home value, and median income of civilian population). The data was split into 80:20 train-test sets. We determined the performance of extreme gradient boosted trees (XGBoost), random forest (RF), and logistic regression (LR) models using sensitivity, specificity, and F-1 score, using 5-fold cross-validation. All models were compared to a baseline prediction model based only on the CDAI score from the previous visit.

Results: A total of 39,155 patients were included in the analysis. The mean (SD) age was 63.7 (13.5) years and 77.6% were female. The mean (SD) visits per patient was 3.9 (1.6). We observed that most patients’ disease activity varied over time – 60.2% of patients experienced a change in CDAI score category at least once. The sensitivity, specificity, and F1-score of the baseline prediction (based only on the last observed CDAI score) vs. the best ML model (XGBoost) were very similar (0.8264, 0.9398, and 0.8234 vs. 0.8237, 0.9390, and 0.8209, respectively) (Table 2). Using XGBoost, the top three variables of importance that were identified were the previous CDAI category, previous raw CDAI score, and a binary feature indicating if the CDAI value was imputed.

Conclusion: ML models may be helpful in predicting RA disease activity in the future, although the performance of our best ML model was very similar to a standard baseline model in predicting CDAI score at a patient’s next visit. Future studies may benefit from utilizing time-varying models such as “long short-term memory”, which better capture the longitudinal nature of EHR data. These tools in conjunction with clinician judgments may allow for early action in managing disease activity for patients with RA.

Disclaimer: Data collection was supported by the ACR’s RISE Registry. The views expressed represent those of the authors, not necessarily those of ACR.

Supporting image 1

Characteristics of included individuals with rheumatoid arthritis in RISE at the first visit in the study period.

Supporting image 2

Model performance in the test set.


Disclosures: E. Tshimanga, None; M. Gianfrancesco, Pfizer; S. Giampanis, Anthem, Apple; J. Li, None; E. Kersey, None; J. Yazdany, AstraZeneca, Gilead, Bristol-Myers Squibb(BMS), Aurinia, Astra Zeneca, Pfizer; B. Norgeot, Anthem; G. Schmajuk, None; Z. Izadi, None.

To cite this abstract in AMA style:

Tshimanga E, Gianfrancesco M, Giampanis S, Li J, Kersey E, Yazdany J, Norgeot B, Schmajuk G, Izadi Z. Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/predicting-disease-activity-in-rheumatoid-arthritis-patients-using-machine-learning-data-from-the-acrs-rise-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-disease-activity-in-rheumatoid-arthritis-patients-using-machine-learning-data-from-the-acrs-rise-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology